Cerevel Therapeutics Holdings Inc (OQ:CERE)

Apr 18, 2024 06:30 am ET
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the first and only...
Jan 29, 2024 01:23 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MGRC, SNCE, VINE, CERE
NEW YORK, Jan. 29, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 29, 2024 09:59 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - E
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 26, 2024 05:41 pm ET
CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE
NEW ORLEANS, Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of  Cerevel Therapeutics (NasdaqCM: CERE) to AbbVie Inc. (NYSE: ABBV).  Under the terms of the proposed transaction, shareholders of Cerevel will receive $45.00 in cash for each share of Cerevel that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 24, 2024 09:45 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates WAVD, CERE, TGAN
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: WaveDancer, Inc. (NASDAQ: WAVD)’s...
Jan 24, 2024 07:30 am ET
Kuehn Law Encourages MDC, WAVD, NS and CERE Investors to Contact Law Firm
NEW YORK, Jan. 24, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 
Jan 23, 2024 01:45 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, SIX, CERE, EGLE
NEW YORK, Jan. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 08, 2024 12:36 pm ET
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in cash is fair to Cerevel shareholders.
Jan 05, 2024 07:44 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WAVD, CSTR, CERE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: WaveDancer, Inc. (NASDAQ: WAVD)’s...
Jan 04, 2024 11:22 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 03, 2024 11:16 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIA, CERE, BRBS, AYX
NEW YORK, Jan. 3, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 02, 2024 05:09 pm ET
Kuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law Firm
NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 
Jan 01, 2024 09:19 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGN, HA, CERE, HOLI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ImmunoGen, Inc. (NASDAQ: IMGN)’s sale...
Dec 27, 2023 07:26 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CERE, WAVD, ICVX, EAR
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Dec 27, 2023 02:51 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, HOLI, ICVX, CVLY
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, Inc....
Dec 26, 2023 10:11 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BVH, CERE, ICVX, RAIN
NEW YORK, Dec. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 26, 2023 06:28 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – BVH, HOLI, CERE, WAVD
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Dec 26, 2023 02:27 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Dec 18, 2023 05:25 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, EGLE, ICVX, RAIN
NEW YORK, Dec. 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 18, 2023 12:36 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE – AYX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Na
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Dec 14, 2023 01:28 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, HOLI, EGLE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, Inc....
Dec 13, 2023 08:00 pm ET
STOCKHOLDER ALERT: Juan Monteverde Encourages the Shareholders of CERE, SRT, WAVD, GRPH to Take Action
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Dec 12, 2023 11:59 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, IMGN, ROVR, GRPH
NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 11, 2023 01:28 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Dec 08, 2023 07:00 pm ET
ALERT: Juan Monteverde Encourages the Shareholders of CERE, PFIN, NWLI, CSTR to Take Action
NEW YORK, Dec. 8, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Dec 08, 2023 04:10 pm ET
CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cerevel Therapeutics (NasdaqCM: CERE) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Cerevel will receive $45.00 in cash for each share of Cerevel that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 08, 2023 12:00 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, ROVR, SIX, BBAI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, Inc....
Dec 07, 2023 11:01 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, SLGC, LAB
NEW YORK, Dec. 7, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 07, 2023 08:31 am ET
Thinking about trading options or stock in Novo Nordisk, Vale, Cerevel Therapeutics, Braze Inc, or Alphabet Inc?
NEW YORK, Dec. 7, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVO, VALE, CERE, BRZE, and GOOG.
Dec 06, 2023 10:52 pm ET
Shareholder Alert: Ademi LLP investigates whether Cerevel Therapeutics has obtained a Fair Price in its transaction with AbbVie
MILWAUKEE, Dec. 6, 2023 /PRNewswire/ -- Ademi LLP is investigating Cerevel (NASDAQ: CERE) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie.
Dec 06, 2023 10:24 pm ET
CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics
NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Julie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. The firm has already identified potential conflicts of interest related to the merger.
Dec 06, 2023 07:33 pm ET
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in cash is fair to Cerevel shareholders.
Dec 06, 2023 03:30 pm ET
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remainCerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipelineEmraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditionsTransaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billionAbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CTNORTH CHICAGO, Ill.
Nov 29, 2023 06:30 am ET
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a tavapadon investor webcast on Monday, December 11, from 10:00 to 11:30 a.m. ET. Cerevel will...
Nov 08, 2023 06:30 am ET
Cerevel Therapeutics to Present at Upcoming Investor Conferences
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that members of the management team will participate in two upcoming investor conferences during the...
Nov 01, 2023 06:30 am ET
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the third quarter ended September 30, 2023 and provided key pipeline and...
Oct 13, 2023 06:30 am ET
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1,...
Oct 11, 2023 10:45 pm ET
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189...
Oct 11, 2023 04:01 pm ET
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering of $400.0 million of shares of...
Aug 29, 2023 06:30 am ET
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healthcare...
Aug 12, 2023 02:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE
Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529,...
Aug 03, 2023 04:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE
Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529,...
Aug 02, 2023 06:30 am ET
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the second quarter ended June 30, 2023 and provided key pipeline and business...
Jul 05, 2023 06:30 am ET
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2023 financial results and business updates on Wednesday, August 2,...
Jun 15, 2023 06:30 am ET
Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer,...
May 10, 2023 06:30 am ET
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO), effective May 15, 2023....
May 03, 2023 06:30 am ET
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Ron Renaud as president and chief executive officer (CEO), and member of the...
Apr 26, 2023 06:30 am ET
Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 2023 BofA...
Apr 11, 2023 06:30 am ET
Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2023 financial results and business updates on Wednesday, May 3, 2023,...
Mar 21, 2023 06:30 am ET
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will participate in a fireside chat at...
Mar 02, 2023 06:30 am ET
Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 43rd...
Feb 22, 2023 06:30 am ET
Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided key...
Feb 01, 2023 06:30 am ET
Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2022 financial results and business updates on Wednesday,...
Jan 09, 2023 06:30 am ET
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present tomorrow, Tuesday, January 10 at 8:15 a.m. PT/11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare...
Jan 04, 2023 06:30 am ET
Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 41st...
Dec 19, 2022 06:30 am ET
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today results from the Phase 1 randomized, double-blind trial studying the effect of emraclidine on 24-hour...
Dec 15, 2022 06:30 pm ET
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the publication of data from its Phase 1b clinical trial of emraclidine, a novel muscarinic M4...
Nov 11, 2022 06:30 am ET
Cerevel Therapeutics to Present at Upcoming Investor Conferences
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences....
Nov 08, 2022 06:30 am ET
Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended September 30, 2022 and provided key pipeline and business...
Oct 19, 2022 06:30 am ET
Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8, 2022, before the U.S....
Sep 06, 2022 06:30 am ET
Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 20th Annual Global Healthcare...
Aug 12, 2022 06:00 am ET
Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes
Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten...
Aug 12, 2022 06:00 am ET
Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock
Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced private...
Aug 10, 2022 04:01 pm ET
Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes
Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced a private offering of $250.0...
Aug 10, 2022 04:01 pm ET
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering...
Aug 08, 2022 08:30 am ET
Thinking about buying stock in Bed Bath & Beyond, Kodiak Sciences, Cerevel Therapeutics, Signify Health, or Eargo?
NEW YORK, Aug. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBBY, KOD, CERE, SGFY, and EAR.
Aug 01, 2022 06:15 am ET
Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended June 30, 2022 and provided key pipeline and business updates....
Jul 25, 2022 05:00 pm ET
Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, 2022, before the U.S....
Jun 15, 2022 06:30 am ET
Cerevel Therapeutics Announces Updates to its Board of Directors
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed Suneet Varma to serve as a member of its board of directors. Mr. Varma succeeds...
May 25, 2022 06:30 am ET
Cerevel Therapeutics to Present at the Jefferies Healthcare Conference
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.D. will participate in a fireside chat at the...
May 10, 2022 06:30 am ET
Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended March 31, 2022 and provided key pipeline and business updates....
Apr 13, 2022 06:30 am ET
Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the U.S....
Mar 31, 2022 06:30 am ET
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced an upcoming oral presentation and three poster presentations at the American Academy of Neurology (AAN)...
Mar 21, 2022 06:30 am ET
Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer, Tony Coles, M.D. will participate in a fireside chat at the...
Mar 01, 2022 06:30 am ET
Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided key...
Feb 16, 2022 06:30 am ET
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S....
Feb 15, 2022 06:30 am ET
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced positive results from its Phase 1 healthy volunteer clinical trial to evaluate darigabat, a novel...
Jan 10, 2022 06:30 am ET
Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present today at 2:15 p.m. ET at the 40th Annual JP Morgan Healthcare Conference. During the presentation,...
Jan 03, 2022 07:00 am ET
Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that Chairperson and Chief Executive Officer Tony Coles, M.D., will present at the upcoming...
Dec 16, 2021 07:00 am ET
Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Herophilus, a leading biotechnology company developing neurotherapeutics to cure complex brain diseases, today...
Nov 10, 2021 06:30 am ET
Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended September 30, 2021 and provided key pipeline and business...
Nov 01, 2021 06:30 am ET
Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it will participate in four upcoming virtual investor conferences during the months of November and...
Oct 20, 2021 06:30 am ET
Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2021 financial results and pipeline updates on Wednesday, November 10,...
Oct 07, 2021 07:00 am ET
Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will host a virtual R&D event today from 10:00 to 11:30 a.m. ET. Presented in a live webcast format, Cerevel will...
Sep 21, 2021 05:00 pm ET
Cerevel Therapeutics Announces Departure of CFO Kathy Yi
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that Kathy Yi has resigned her position as chief financial officer to pursue other personal and...
Sep 10, 2021 07:00 am ET
Cerevel Therapeutics to Host Virtual R&D Event on October 7
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a virtual R&D event on Thursday, Oct. 7 from 10:00 to 11:30 a.m. ET. Hosted in a live webcast...
Sep 01, 2021 07:00 am ET
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in two upcoming virtual investor conferences during the...
Aug 11, 2021 06:30 am ET
Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended June 30, 2021 and provided key pipeline and business updates....
Jul 30, 2021 07:00 am ET
Cerevel Therapeutics Announces Redemption of Public Warrants
Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that on August 30, 2021 at 5:00 p.m. ET, it will redeem all of its outstanding...
Jul 22, 2021 07:00 am ET
Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2021 financial results and provide a pipeline update on Wednesday,...
Jul 02, 2021 10:45 am ET
Thinking about buying stock in ContextLogic, Exela Technologies, Citius Pharmaceuticals, Overseas Shipholding, or Cerevel Therapeutics?
NEW YORK, July 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, XELA, CTXR, OSG, and CERE.
Jul 01, 2021 09:50 pm ET
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of common...
Jul 01, 2021 09:31 am ET
Thinking about buying stock in Kintara Therapeutics, US Well Services, Transocean, Marathon Oil, or Cerevel Therapeutics?
NEW YORK, July 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KTRA, USWS, RIG, MRO, and CERE.
Jun 29, 2021 04:24 pm ET
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that is has commenced an underwritten public offering of 14,000,000 shares of its common stock. In...
Jun 29, 2021 08:30 am ET
Thinking about buying stock in Exela Technologies, Cerevel Therapeutics, Verb Technology, Avinger, or VBI Vaccines?
NEW YORK, June 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, CERE, VERB, AVGR, and VBIV.
Jun 29, 2021 06:30 am ET
Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced positive results from its Phase 1b clinical trial of CVL-231, a novel muscarinic M4-selective Positive...
Jun 15, 2021 07:00 am ET
Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CVL-871, a D1/D5...
May 27, 2021 07:00 am ET
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it will participate in two upcoming virtual investor conferences during the month of June....
May 17, 2021 06:30 am ET
Cerevel Therapeutics Reports First Quarter 2021 Financial Results and Business Updates
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended March 31, 2021 and provided key pipeline and business...
May 04, 2021 07:00 am ET
Cerevel Therapeutics Announces the Appointment of Scott M. Akamine as Chief Legal Officer
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Scott M. Akamine as chief legal officer, effective May 24, 2021. An accomplished...
Apr 29, 2021 07:00 am ET
Cerevel Therapeutics to Report First Quarter 2021 Financial Results on Monday, May 17, 2021
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2021 financial results on Monday, May 17, 2021, before the U.S....
Apr 21, 2021 07:00 am ET
Cerevel Therapeutics Appoints Abraham N. Ceesay as President
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Abraham N. Ceesay to the newly-created role of president, effective May 3, 2021. Mr. Ceesay brings...
Apr 13, 2021 06:30 am ET
Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced an up to $125 million non-dilutive financing transaction with NovaQuest and Bain Capital to fund the...
Mar 24, 2021 06:30 am ET
Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2020 Financial Results
Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided key...
Mar 22, 2021 07:00 am ET
Cerevel Therapeutics to Present at the Stifel 3rd Annual CNS Day Event
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that Chairperson and Chief Executive Officer, Tony Coles, M.D. will participate in a fireside chat at the...
Feb 24, 2021 07:00 am ET
Cerevel Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2020 financial results on Wednesday, March 24, 2021,...
Feb 23, 2021 07:00 am ET
Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference. Date:...
Jan 28, 2021 07:00 am ET
Cerevel Therapeutics Hosts Inaugural Virtual R&D Event to Review Darigabat (CVL-865) and Provide Overview of Key Preclinical Programs
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will host the first in a series of virtual R&D events today from 9:00 to 11:00 a.m. EST. In a live webcast, Cerevel...
Jan 21, 2021 07:00 am ET
Cerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of Directors
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed the Honorable Deval Patrick and Deborah Baron to serve as independent members of its Board of...
Dec 14, 2020 07:00 am ET
Cerevel Therapeutics to Host Inaugural Virtual R&D Event
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host the first in a series of virtual R&D events on Thursday, January 28 from 9:00 to 11:00 a.m....
Dec 08, 2020 07:00 am ET
Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has added Ruth McKernan, Ph.D., CBE, FMedSci, to serve as an independent member of its Board...
Dec 04, 2020 07:00 am ET
Cerevel Therapeutics to Host Investor Webcast Moderated by Stifel
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a live webcast providing a current corporate overview, followed by a moderated question and...
Nov 23, 2020 07:00 am ET
Cerevel Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside chat at the...
Nov 16, 2020 06:30 am ET
Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced financial results for the third quarter ended September 30, 2020 and provided recent business updates....
Nov 04, 2020 07:00 am ET
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming virtual investor conferences during...
Oct 30, 2020 07:00 am ET
Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson’s Disease
Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the first participants have been dosed in all three of the clinical trials in their Phase 3...
Oct 28, 2020 07:00 am ET
Cerevel Therapeutics Debuts as Publicly Traded Neuroscience Company
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the completion of its business combination with Arya Sciences Acquisition Corp II (Nasdaq: ARYBU; or “Arya II”), a special...
Aug 01, 2016 01:54 pm ET
Land O'Lakes, Inc. Completes Acquisition of Ceres, Inc.
ARDEN HILLS, Minn., Aug. 1, 2016 /PRNewswire/ -- Land O'Lakes, Inc. today completed its previously announced acquisition of Ceres, Inc. (NASDAQ: CERE) ("Ceres").
Jun 17, 2016 08:59 am ET
Land O’Lakes, Inc. to Acquire Ceres, Inc. in Cash Tender Offer
ARDEN HILLS, Minn. and THOUSAND OAKS, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- Land O’ Lakes, Inc. and Ceres, Inc. (Nasdaq:CERE) announced today that they have signed a definitive merger agreement under which Land O'Lakes will acquire all of the outstanding capital stock of Ceres in a transaction valued at approximately $17.2 million (including amounts payable to holders of certain warrants to acquire Ceres common stock). Under the terms of the merger agreement, Land O’Lakes (through its wholly owned subsidiary, Roman Merger Sub, Inc.) will commence a tender offer for all outstanding shar...
Apr 28, 2016 08:15 am ET
Ceres Sugarcane Traits Approved for Field Testing in Brazil
THOUSAND OAKS, Calif., April 28, 2016 /PRNewswire/ -- Ceres, Inc. (Nasdaq: CERE), an agricultural biotechnology company, today announced that the company has received approval to initiate field testing of its biotech sugarcane in Brazil, the world's largest producer of sugarcane.
Apr 26, 2016 08:15 am ET
Ceres Awarded Two U.S. Patents for Innovative Crop Traits
THOUSAND OAKS, Calif., April 26, 2016 /PRNewswire/ -- Ceres, Inc. (Nasdaq: CERE), an agricultural biotechnology company focused on forage crops, has been awarded two patents related to crop traits that can increase and protect crop yields under less-than-optimal environmental conditions. The traits have potential application in numerous food, feed and fiber crops, such as corn, soybean, forage sorghum and cotton.
Apr 18, 2016 08:35 am ET
Ceres Expands Distribution Network to Carry Growing Seed Product Line
THOUSAND OAKS, Calif., April 18, 2016 /PRNewswire/ -- Ceres, Inc. (Nasdaq: CERE), an agricultural biotechnology focused on forage and feed crops, announced today that it has expanded its distribution network for its forage sorghum seed products. The announcement follows favorable product performance results from its new line of improved hybrids, which are used to grow hay and silage for dairy and beef cattle.
Feb 24, 2016 07:30 am ET
Ceres Reports That Trial Results 'Exceeded Expectations' for Its Leading Trait
THOUSAND OAKS, Calif., Feb. 24, 2016 /PRNewswire/ -- Ceres, Inc. (Nasdaq: CERE), an agricultural biotechnology company focused on forage and feed crops, today announced favorable results from its 2015 sorghum trait evaluations in the United States, where a second year of testing demonstrated significant yield advantages from its leading biomass trait. The company indicated that this was a key milestone for its trait pipeline.
Feb 17, 2016 07:00 am ET
Ceres Receives Positive Response from USDA Regarding Corn Traits
THOUSAND OAKS, Calif., Feb. 17, 2016 /PRNewswire/ -- Ceres, Inc. (Nasdaq: CERE), an agricultural biotechnology company focused on forage and feed crops, announced that its petition to have a number of its traits for corn deemed non-regulated has been successful.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.